Last reviewed · How we verify

GS010 — Competitive Intelligence Brief

GS010 (GS010) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gene therapy (AAV-mediated mitochondrial gene therapy). Area: Ophthalmology / Rare Genetic Disease.

phase 3 Gene therapy (AAV-mediated mitochondrial gene therapy) ND4 gene (NADH dehydrogenase subunit 4) Ophthalmology / Rare Genetic Disease Biologic Live · refreshed every 30 min

Target snapshot

GS010 (GS010) — GenSight Biologics. GS010 is a gene therapy that delivers a functional copy of the ND4 gene to restore mitochondrial function in retinal cells affected by Leber hereditary optic neuropathy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GS010 TARGET GS010 GenSight Biologics phase 3 Gene therapy (AAV-mediated mitochondrial gene therapy) ND4 gene (NADH dehydrogenase subunit 4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gene therapy (AAV-mediated mitochondrial gene therapy) class)

  1. GenSight Biologics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GS010 — Competitive Intelligence Brief. https://druglandscape.com/ci/gs010. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: